TransMedics Group, Inc.
TMDX
Updated: 23/09/2026, 22:03:09
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
No summaries found.
- Share price
- $87.00
- Market cap
- $3.01B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Waleed H. Hassanein
- Employees
- 898
- IPO date
- 02/05/2019
- Beta
- 1.884
- Last dividend
- $0.00
- Day range
- $85.11 – $89.19
- 52-week range
- $60.11 – $156.00
- 1-day performance
- -1.21%
- 1-year performance
- 44.75%
- Current drawdown (1Y)
- -44.23%
- CIK
- 0001756262
- CUSIP
- 89377M109
- ISIN
- US89377M1099
- Created
- 07/12/2025, 14:35:39
- Last update
- 23/09/2026, 22:03:09
Track TransMedics Group, Inc. with an AI analyst
See which prediction-market events move TMDX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
TransMedics: Why I'm Still Bullish After The Collapse
Seeking Alpha • STOCK • 09/06/2026, 11:44:11
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Zacks Investment Research • STOCK • 28/05/2026, 16:01:10
TransMedics: Despite Earnings Miss, Growth Story Remains Intact
Seeking Alpha • STOCK • 25/05/2026, 15:28:13
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
Zacks Investment Research • STOCK • 06/05/2026, 14:55:31
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 22:41:15
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research • STOCK • 05/05/2026, 22:01:16
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Zacks Investment Research • STOCK • 25/03/2026, 12:36:09
TransMedics: Rapidly Scaling Business Nears Free Cash Flow Breakeven
Seeking Alpha • STOCK • 16/03/2026, 05:30:02
TransMedics: Numb Reaction To Extraordinary Fundamentals
Seeking Alpha • STOCK • 09/03/2026, 11:20:42
TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
The Motley Fool • STOCK • 08/03/2026, 06:22:00
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
The Motley Fool • STOCK • 28/02/2026, 13:30:00
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
PRNewsWire • STOCK • 27/02/2026, 08:00:00